Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study

by Hema Sekhar, Rohit Kochhar, Bernadette Carrington, Thomas Kaye, Damian Tolan, Mark P. Saunders, Matthew Sperrin, David Sebag-Montefiore, Marcel van Herk, Andrew G. Renehan
Published 2020-11-01

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer

by Gordon C. Jayson, Cong Zhou, Alison Backen, Laura Horsley, Kalena Marti-Marti, Danielle Shaw, Nerissa Mescallado, Andrew Clamp, Mark P. Saunders, Juan W. Valle, Saifee Mullamitha, Mike Braun, Jurjees Hasan, Delyth McEntee, Kathryn Simpson, Ross A. Little, Yvonne Watson, Susan Cheung, Caleb Roberts, Linda Ashcroft, Prakash Manoharan, Stefan J. Scherer, Olivia del Puerto, Alan Jackson, James P. B. O’Connor, Geoff J. M. Parker, Caroline Dive
Published 2018-11-01

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

by Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Andrew H Briggs, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, Ashita Waterston, Louise Medley, Charles Wilson, Richard Ellis, Sharadah Essapen, Amandeep S Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul
Published 2019-12-01